Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.

Epidermal-growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK) with a significant role in cell survival. EGFR is upregulated in various cancer cells and known as a druggable target. Gefitinib is a first-line TK inhibitor used against metastatic non-small cell lung cancer (NSCLC).

In silico target specific design of potential quinazoline-based anti-NSCLC agents.

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In spite of great advances, treatment of the disease is a medical challenge. Epidermal-growth factor receptor (EGFR) has been taken as a promising cell surface target to develop anti-NSCLC therapies.

Structural Insight into Privileged Heterocycles as Anti- and .

Trypanosomiasis is caused by parasitic protozoan trypanosomes in vertebrates. T. cruzi and T.

Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016-2020).

Fungal infections have greatly contributed to infectious-related deaths in the past century. This issue has become worse with the advent of immunity-impairing conditions such as HIV. The eukaryote nature of fungal pathogens makes them harder to eradicate than bacterial infections.